SEC Form 4 filed by EVP & Chief Financial Officer Mcgrew Matthew

$DHR
Industrial Machinery/Components
Industrials
Get the next $DHR alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
McGrew Matthew

(Last) (First) (Middle)
2200 PENNSYLVANIA AVENUE, NW
SUITE 800W

(Street)
WASHINGTON DC 20037

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
DANAHER CORP /DE/ [ DHR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP & Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
03/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee stock option (right to buy) $207.76 03/01/2025 A 30,943 (1) 03/01/2035 Common Stock 30,943 $0 30,943 D
Explanation of Responses:
1. One half of the options granted become exercisable on each of the third and fourth anniversaries of the grant date, which is March 1, 2025.
Remarks:
/s/ James F. O'Reilly, attorney-in-fact for Matthew McGrew 03/04/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $DHR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$DHR

DatePrice TargetRatingAnalyst
3/21/2025$260.00Neutral → Buy
Goldman
3/14/2025$260.00Hold → Buy
Stifel
2/3/2025Outperform → Mkt Perform
Raymond James
12/23/2024Sector Perform
Scotiabank
12/19/2024$275.00Buy
Guggenheim
12/13/2024$290.00Neutral → Buy
BofA Securities
10/31/2024$285.00Peer Perform → Outperform
Wolfe Research
10/1/2024$315.00Overweight
Stephens
More analyst ratings

$DHR
Press Releases

Fastest customizable press release news feed in the world

See more
  • Danaher Schedules First Quarter 2025 Earnings Conference Call

    WASHINGTON, March 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2025 on Tuesday, April 22, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call. You

    $DHR
    Industrial Machinery/Components
    Industrials
  • Beckman Coulter Announces FDA clearance of DxC 500i Clinical Analyzer, an integrated Clinical Chemistry and Immunoassay System

    The new DxC 500i Analyzer Offers Flexibility and Scalability with Broad Chemistry and Immunoassay Assay Menu BREA, Calif., March 10, 2025 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, today announced that the new DxC 500i Clinical Analyzer, an integrated clinical chemistry and immunoassay analyzer, received 510(k) clearance from the U.S. Food and Drug Administration. The DxC 500i combines advanced technology with an intuitive user interface, ensuring that laboratories of all sizes can meet the growing demands of modern healthcare. With throughput of up to 800 clinical chemistry tests per hour and 100 immunoassay tests per hour, this analyzer delivers precise and

    $DHR
    Industrial Machinery/Components
    Industrials
  • Danaher to Present at TD Cowen Health Care Conference

    WASHINGTON, Feb. 25, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the TD Cowen Healthcare Conference in Boston, Massachusetts on Wednesday, March 5, 2025 at 10:30 a.m. ET. The event will be simultaneously webcast and can be accessed on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important h

    $DHR
    Industrial Machinery/Components
    Industrials

$DHR
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$DHR
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$DHR
SEC Filings

See more

$DHR
Leadership Updates

Live Leadership Updates

See more
  • Danaher Announces Appointment of Charles Lamanna to Danaher Board

    WASHINGTON, Feb. 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced today that it has appointed Charles Lamanna to its Board of Directors and to the Board's Science & Technology Committee. Mr. Lamanna is currently Corporate Vice President, Business & Industry Copilot at Microsoft (NASDAQ:MSFT), where he drives product innovation in AI-powered business applications, low-code platforms, and autonomous agents. He oversees the design, product development, and engineering of some of Microsoft's most transformative technologies, including Power Platform, Dynamics 365, and Copilot Studio. Prior to that, Mr. Lamanna was the founder and CEO of MetricsHub, one of the first public cloud

    $DHR
    $MSFT
    Industrial Machinery/Components
    Industrials
    Computer Software: Prepackaged Software
    Technology
  • Compass Minerals Announces Senior Leadership Team Appointments

    Patrick Merrin named Chief Operations Officer and Peter Fjellman named Chief Financial Officer Compass Minerals (NYSE:CMP), a leading global provider of essential minerals, today announced the appointment of Patrick Merrin, a seasoned operating executive in the mining industry, as the company's new chief operations officer (COO) and Peter Fjellman, who has decades of experience in senior finance roles, as its new chief financial officer (CFO). Merrin's appointment is effective March 3 and fills the COO position which has been open since June 2024. Fjellman, whose appointment is effective immediately, succeeds Jeff Cathey who has decided to depart Compass Minerals due to personal reasons.

    $CMP
    $DHR
    $GXO
    $XPO
    Mining & Quarrying of Nonmetallic Minerals (No Fuels)
    Industrials
    Industrial Machinery/Components
    Transportation Services
  • Danaher Announces Two New Centers of Innovation in Diagnostics to Transform Precision Medicine Development

    DH Diagnostics LLC Centers aim to accelerate drug development by speeding and streamlining development and commercialization of companion diagnostics.Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified laboratories will bring technologies and assays from multiple Danaher subsidiaries together under a single roof.WASHINGTON, July 17, 2024 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher"), a global science and technology innovator, announced the launch of two new Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified labs intended to accelerate the development of Companion Diagnostics (C

    $DHR
    Industrial Machinery/Components
    Industrials

$DHR
Financials

Live finance-specific insights

See more
  • Danaher Schedules First Quarter 2025 Earnings Conference Call

    WASHINGTON, March 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2025 on Tuesday, April 22, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call. You

    $DHR
    Industrial Machinery/Components
    Industrials
  • Danaher Increases Quarterly Dividend

    WASHINGTON, Feb. 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on April 25, 2025 to holders of record on March 28, 2025. This reflects an 18.5% increase over the previous dividend payment of $0.27. ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - a

    $DHR
    Industrial Machinery/Components
    Industrials
  • Danaher Reports Fourth Quarter and Full Year 2024 Results

    WASHINGTON, Jan. 29, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) (the "Company") today announced results for the fourth quarter and full year 2024.  All results in this release reflect only continuing operations unless otherwise noted. Key Fourth Quarter 2024 Results Net earnings were $1.1 billion, or $1.49 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $2.14.Revenues increased 2.0% year-over-year to $6.5 billion and non-GAAP core revenue increased 1.0%.Operating cash flow was $2.0 billion and non-GAAP free cash flow was $1.5 billion.Key Full Year 2024 Results Net earnings were $3.9 billion, or $5.29 per diluted common share and non-GAAP ad

    $DHR
    Industrial Machinery/Components
    Industrials

$DHR
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more